Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:approves |
gptkb:2020
gptkb:COVID-19 |
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:clinical_use |
hospitalized patients with severe COVID-19
|
| gptkbp:contraindication |
hypersensitivity to remdesivir
|
| gptkbp:developed_by |
gptkb:Gilead_Sciences
|
| gptkbp:distribution |
global
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Veklury
|
| gptkbp:indication |
treatment of COVID-19
|
| gptkbp:ingredients |
remdesivir
|
| gptkbp:invention |
gptkb:Gilead_Sciences
|
| gptkbp:marketed_as |
remdesivir
|
| gptkbp:mechanism_of_action |
RNA polymerase inhibitor
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:side_effect |
nausea
liver enzyme elevation hypersensitivity reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:bfsParent |
gptkb:Gilead_Sciences
|
| gptkbp:bfsLayer |
4
|